Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical R…

Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results. “For biomedical and clinical research laboratories that are involved in fighting the pandemic, this kit offers a useful research tool for de...